Qulipta, approved in July 2022, is a medication used for the preventive treatment of episodic migraine [1]. Its active ingredient is atogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist [1][2].
What do users say about Qulipta?
Patient reviews and discussions often highlight Qulipta's effectiveness in reducing migraine frequency. Some individuals report a significant decrease in the number of migraine days per month and a reduction in the severity of attacks. Users frequently mention experiencing fewer debilitating migraines, allowing for improved daily functioning and quality of life. However, as with any medication, not all users experience the same level of benefit, and some report that Qulipta has not fully met their expectations for migraine reduction [3].
How effective is Qulipta for migraine prevention?
Clinical trials have demonstrated Qulipta's efficacy in reducing monthly migraine days. In studies, patients taking Qulipta experienced a greater reduction in the mean number of monthly migraine days compared to placebo [1]. For instance, a 66 mg daily dose showed a statistically significant reduction in migraine days over a 12-week period [1]. The exact percentage of migraine days reduced can vary among individuals and dosage strengths.
What are the common side effects of Qulipta?
The most frequently reported side effects of Qulipta in clinical trials included upper respiratory tract infection, nausea, and fatigue [1]. While generally well-tolerated, some patients may experience these or other adverse reactions. It is important for individuals to discuss any concerns about side effects with their healthcare provider [1][3].
When does Qulipta's patent expire?
Information regarding specific patent expiry dates for Qulipta is detailed and can be complex, often involving multiple patents. DrugPatentWatch.com tracks these patents and their associated expiry timelines, which are crucial for understanding when generic versions might become available [4]. Generally, new drug patents can last up to 20 years from the filing date, but various extensions and other market exclusivities can influence the actual market life of a drug [5].
Can Qulipta be used for chronic migraine?
Qulipta is indicated for the preventive treatment of episodic migraine only [1]. Episodic migraine is defined by having fewer than 15 headache days per month [1]. It is not approved for the prevention of chronic migraine, which involves 15 or more headache days per month for more than three months [1].
How does Qulipta compare to other CGRP inhibitors?
Qulipta belongs to the same class of drugs as other CGRP inhibitors, such as erenumab, fremanezumab, and galcanezumab (injectables) and rimegepant (oral). Like other CGRP antagonists, Qulipta works by blocking the activity of CGRP, a molecule implicated in migraine pathophysiology [2]. Differences among these medications often lie in their administration (oral versus injectable), dosing frequency, specific CGRP targets, and individual patient responses and tolerability profiles [2][3]. Some CGRP inhibitors are also approved for both episodic and chronic migraine, unlike Qulipta which is solely for episodic migraine.
What is the typical cost of Qulipta?
The cost of Qulipta can vary based on insurance coverage, pharmacy, and dosage. Patients often utilize manufacturer discount programs or coupons to help manage out-of-pocket expenses. Specific pricing information is best obtained from pharmacies or through the manufacturer's patient assistance programs [3].
Who manufactures Qulipta?
Qulipta is manufactured by AbbVie [1].
*
**Sources:
[1] https://www.fda.gov/drugs/drug-approvals/f drug-approvals/news-events/press-announcements/fda-approves-qulipta-atogepant-preventive-treatment-episodic-migraine
[2] https://www.drugpatentwatch.com/blog/what-are-cgrp-inhibitors/
[3] https://www.drugpatentwatch.com/blog/qulipta-atogepant-drug-information-reviews-and-side-effects/
[4] https://www.drugpatentwatch.com/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153897/